- Research article
- Open Access
- Open Peer Review
One life ends, another begins: Management of a brain-dead pregnant mother-A systematic review-
BMC Medicinevolume 8, Article number: 74 (2010)
An accident or a catastrophic disease may occasionally lead to brain death (BD) during pregnancy. Management of brain-dead pregnant patients needs to follow special strategies to support the mother in a way that she can deliver a viable and healthy child and, whenever possible, also be an organ donor. This review discusses the management of brain-dead mothers and gives an overview of recommendations concerning the organ supporting therapy.
To obtain information on brain-dead pregnant women, we performed a systematic review of Medline, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL). The collected data included the age of the mother, the cause of brain death, maternal medical complications, gestational age at BD, duration of extended life support, gestational age at delivery, indication of delivery, neonatal outcome, organ donation of the mothers and patient and graft outcome.
In our search of the literature, we found 30 cases reported between1982 and 2010. A nontraumatic brain injury was the cause of BD in 26 of 30 mothers. The maternal mean age at the time of BD was 26.5 years. The mean gestational age at the time of BD and the mean gestational age at delivery were 22 and 29.5 weeks, respectively. Twelve viable infants were born and survived the neonatal period.
The management of a brain-dead pregnant woman requires a multidisciplinary team which should follow available standards, guidelines and recommendations both for a nontraumatic therapy of the fetus and for an organ-preserving treatment of the potential donor.
Brain death (BD) as "coma dépassé" was first defined by Mollaret and Goulon in 1959 , and it remains the medically and legally accepted framework for the diagnosis of death. Death is pronounced on the basis of well-defined clinical examinations followed by confirmatory technical tests. Recent improvements in life support technology and critical care management make it possible to maintain the patient's vital functions after BD. The question whether to offer life support to brain-dead patients and how long it should be provided has become a controversial ethical issue. The issue is still more complex when BD occurs during pregnancy. Of course, the incidence of BD in pregnant women is very low and there are only few case reports. As shown by Suddaby et al. , of 252 brain-dead patients, only 5 (2.8%) cases involved pregnant women between 15 and 45 years of age.
When confronted with BD in a pregnant woman, physicians must primarily focus on saving the life of the fetus, and therefore the treatment protocol should give special recommendations on how to support the mother in a way that she can deliver a viable and healthy child. After delivery, brain-dead pregnant women may also be candidates for organ donation. Therefore, two aspects must be considered in case of maternal BD: supporting the fetus until successful delivery and, if possible, supporting the brain-dead mother as an organ donor. Hence, if the mother and the fetus are regarded as two distinct organisms, maintaining the vital functions of a brain-dead pregnant patient may be ethically justifiable to support both the birth of a child and possible organ donation. In such a situation, various clinical disciplines such as neurosurgery, intensive care medicine, obstetrics, neonatology, anesthesiology, transplantation surgery and an ethics committee should work together to minimize maternal and fetal morbidity as well as mortality.
Since only a few reported cases are to be found in the medical literature, most approaches to managing a brain-dead mother remain experiential and relatively little publicized. In this article, we review the available cases of prolonged somatic support in brain-dead pregnant women and analyze when and under which circumstances the pregnancy should be maintained and what challenges are to be faced. To present a protocol to support such patients, we discuss the management of the brain-dead mother and fetus, related recommendations and legal and ethical issues.
We performed a systematic review of Medline (1975-2010), EMBASE (1982-2010) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2010) for relevant citations. Key words used in electronic searching included "maternal brain death," "pregnancy," "brain death," "management of brain death" and "fetal monitoring." Reference lists of retrieved relevant articles were screened for other studies. Additionally, to include all existent studies, we also contacted experts in the related fields of brain death and pregnancy.
Study selection and data extraction
All studies which reported at least one case of maternal brain death during pregnancy were eligible for inclusion. We excluded studies dealing with pregnancy in a persistent vegetative state because brain death adds complexities to pregnancy that are very different from a persistent vegetative state, calling for different medical management and obstetric strategies, as well as other legal and ethical considerations. Furthermore, we excluded studies which only discussed ethical and legal issues and studies providing insufficient data. There were no language restrictions. One reviewer (ME) screened all titles and abstracts to assess whether they were potentially eligible for inclusion and whether full text was required. Then abstracts and full texts for all potentially eligible studies were reviewed by two researchers (ME and EK), who independently evaluated these articles and extracted their data. Any disagreement during study selection and the data extraction process was resolved by discussion with a third author (AM). According to our search of the medical literature, 30 cases of maternal BD (19 case reports and 1 case series) were reported between 1982 and 2010. The collected data included the age of the mother, the cause of BD, maternal medical complications, gestational age at BD, duration of life support and gestational age at delivery. In addition, we evaluated the indication of delivery, mode of delivery, neonatal outcome and organ donation by the mothers, as well as the transplant outcome. In our analysis, we particularly focused on the critical care management of brain-dead mothers such as respiratory and cardiovascular support, endocrinology and thermoregulation, nutritional support and organ donation, as well as aspects of obstetric management, including fetal monitoring.
The statistical analysis was performed using SPSS 14.0 software for Windows (Stata Corp., College Station, TX, USA). All statistical data regarding maternal age, duration of maternal support, gestational age and fetal birthweight were expressed as means.
Figure 1 summarizes the process of literature identification and selection. According to our search, between 1982 and 2010, 19 case reports and 1 case series were published. In Table 1, we summarize the 30 reported cases of extended maternal life support after BD with pregnancy and the resulting neonatal outcomes.
Maternal and obstetric outcome
In the 30 reported cases, the maternal mean age at the time of BD was 26.5 years. Only three mothers were in the high-risk pregnancy category (age <18 or age >35 yr) with respect to their age. Two mothers were 18 years old and a third one was 40 years old at the time of pregnancy. Trauma was the cause of BD in 4 of 30 mothers, and the other 26 died of nontraumatic brain injuries. The mean duration of maternal support was 38.3 days (range, 2-107 days). In two cases, children were delivered on the second day after BD was diagnosed. Conversely, in two reports, mothers were supported for more than 100 days before delivery. The mean gestational age at the time of BD was 22 weeks (range, 1-40 wk). In 10 of 19 reported cases, the baby was delivered later than week 28. The mean gestational age at delivery was 29.5 weeks (range, 26-33 wk). During extended life support, patients developed several complications, including infection, hemodynamic instability, diabetes insipidus (DI), panhypopituitarism, poikilothermia, metabolic instability, acute respiratory distress syndrome and disseminated intravascular coagulation (Table 1). The indications for delivery in all reported cases were maternal or fetal difficulties, including maternal hemodynamic instability (seven cases), fetal distress (three cases), oligohydramnion (two cases), intrauterine growth retardation (one case) and abnormal pattern of the placental structure (one case). In two cases in which maternal BD began at week 13 of gestational age, spontaneous abortion occurred at weeks 13 and 19. In four cases, there was intrauterine death. A cesarean section was the mode of delivery in all cases which resulted in live-born fetuses (Table 1).
Fetal and neonatal outcome
In 12 (63%) of 19 reported cases, the prolonged somatic support led to the delivery of a viable child. We did not find any information about the fate of the fetuses in the published case series. Children who were born included 1 female and 10 male infants. No information regarding sex was given about one infant. The average birthweight was 1,384 g (range, 815-2,083 g), and the mean Apgar score was 7 and 8 at 1 and 5 minutes, respectively. Congenital defects were reported for only one infant, who was diagnosed with fetal hydantoin syndrome resulting from previous chronic phenytoin usage by the mother. Four infants required temporary mechanical ventilation because of neonatal respiratory distress syndrome or pneumonia. Fungemia was diagnosed in one infant, and he was treated with amphotericin B. However, not every infant was sufficiently followed to determine the long-term effects of prolonged maternal life support. Postnatal follow-up up to 24 months was available only for six infants. All of them developed normally and apparently had no problems related to their exceptional intrauterine circumstances (Table 1).
Organ procurement and transplant outcome
In three reported cases after successful delivery, organ donation from the brain-dead mother was carried out. In two cases, organ procurement was accomplished after the intrauterine death of the fetus. In yet another five cases, organ donation was performed, but no report about the status of the fetus was provided. In six patients, consent was given by the patient's family to donate heart, lung, liver, pancreas and kidneys. In four donors, no information was given concerning donated organs. The 1-year graft survival in the reported cases was excellent. Only one liver and one pancreas were lost in two patients owing to their primary nonfunction. Finally, in all cases, maternal somatic support was ended either after delivery or after organ donation (Table 1).
Clinically, following the onset of BD, it is possible to sustain a brain-dead mother's somatic functions over a longer period. Manifold physiological changes occurring during pregnancy and brain death, as well as the prolonged hospital stay after BD, present enormous challenges, however, both for the treating clinicians and for the family. The important question is from which gestational age onward should the pregnancy be supported? At present, it seems that there is no clear lower limit to the gestational age which would restrict the physician's efforts to support the brain-dead mother and her fetus. As reported by Slattery et al. , a fetus born before 24 weeks of gestation has a limited chance of survival. At 24, 28 and 32 weeks, a fetus has approximately a 20-30%, 80% and 98% likelihood of survival with a 40%, 10% and less than 2% chance of suffering from a severe handicap, respectively. Therefore, depending on maternal stability and fetal growth, the decision must be made on an individual basis. According to our findings, prolonged somatic support can lead to the delivery of a viable child with satisfactory Apgar score and birthweight. Such children can also develop normally without any problems resulting from their intrauterine conditions. Furthermore, after the delivery, mothers could be considered as potential organ donors. In Figure 2, we summarize the recommendations for the critical care management of brain-dead pregnant women. This schema is not a definitive guideline, because the technical support and the experience of the responsible medical team must also be taken under consideration. Also, the number of reported cases is too small to define the rate at which intensive care support of the brain-dead mother can result in a healthy infant. The percentage of successful cases cannot be determined, because there are no reports describing failure of intensive maternal support from all medical centers. Finally, it cannot be established whether a relative infrequency of cases such as those that we found in the published literature reflects the rarity of the event, perfect success in all prior situations, reluctance to initiate intensive efforts required to support the brain-dead patient or simply publication bias.
However, we maintain that the management of a brain-dead pregnant woman should follow the existent standards, guidelines and recommendations both for nontraumatic therapy for the fetus and organ-preserving treatment for the donor [4–6]. What follows here is the summary of these guidelines and recommendations.
In the initial phase of BD, tachycardia was detected in less than half of the patients [7, 8]. However, subsequently the heart rate slowed in all of these patients as factors such as hypothermia and subclinical myocardial hypoxia antagonized the sympathetic activation occurring during the initial phase of BD . Hypertension in this situation is a rare, usually self-limiting event. In prolonged hypertension, short-acting substances such as urapidil or nitroprusside were applied [9, 10]. Typically, at some point, BD patients also develop hypotension . The initial treatment for hypotension consists of aggressive fluid replacement, which is usually done with crystalloids such as lactated Ringer's solution in normal (0.9%) or half-normal (0.45%) saline solutions. Recent studies suggest that to keep intravascular volume and colloid oncotic pressure within physiological ranges , hydroxyethyl starch can also be applied in case of a negative effect on the renal graft function . However, it must be kept in mind that low oncotic pressure and hypoalbuminemia can cause pulmonary edema [12, 13]. Field et al.  recommended that in case of pulmonary edema a Swan-Ganz catheter be used to differentiate cardiogenic pulmonary edema from acute respiratory distress syndrome (ARDS) and to guide fluid management. In addition, extensive hemodynamic monitoring such as Pulscontour Continuous Cardiac Output (PiCCO™) should be considered [4, 15]. Fluid-resistant hypotension can be treated using continuous intravenous dopamine receptor agonists, which should be titrated until a mean arterial pressure of 80 to 110 mmHg is reached .
In maternal BD, special attention needs to be paid to mechanical ventilation. To facilitate the elimination of carbon dioxide from the fetus and as a result of the progesterone effect on the respiratory center, the pregnant mother develops hypocarbia mediated by an increase in tidal volume and respiratory rate. Hypocarbia is compensated by an increase in excretion of bicarbonates by the kidneys . Maternal carbon dioxide tensions, a tidal volume and respiratory rate should be maintained in the normal pregnancy range of 28 to 31 mmHg, 6 to 8 mL/kg and 10 to 12/min, respectively . The fraction of inspired oxygen should be kept in a range maintaining the arterial oxygen saturation above 90%.
Seventy-eight percent of brain-dead patients who were kept alive for more than a few days developed central diabetes insipidus (DI) resulting from posterior pituitary gland failure . Administration of vasopressin and aggressive volume replacement should be performed for the treatment of DI . Howlett et al.  reported a decrease in serum triiodothyronine (T3) in 81% and in serum thyroxin (T4) in 29% of BD dead organ donors. Therefore, especially in brain-dead pregnant women T3/T4 substitution should be adjusted according to laboratory examinations. Adrenal insufficiency causes hypotension and should be treated with methylprednisolone. To avoid prolonged exposure of the fetus to glucocorticoids during maternal somatic support, prednisone or methylprednisone should be used, as they do not readily cross the placenta . Furthermore, since hyperglycemia is also observed during BD as a result of stress-related peripheral insulin resistance, insulin substitution may be needed to achieve normoglycemia .
According to Smith et al. , the majority of brain-dead patients develop hypothermia. It is recommended that the patient be rewarmed passively using warming blankets or by warming of fluids. Following infections, brain-dead patients might also develop hyperthermia. In general, the inability to maintain body temperature and poikilothermia (body temperature that is dependent on the environment's temperature) accompany brain-dead patients [23, 24].
The nutritional needs of a pregnant woman before and after BD are not the same. Basal energy expenditure (BEE) in pregnancy is 655 Kcal + (9.6 × weight (kg) + [1.8 × height (cm) -- 4.7 age (year)]) [25–27]. A weight gain of 10 to 15 kg accompanies a normal pregnancy . A brain-dead pregnant woman will expend about 75% of a healthy pregnant woman's BEE . Nutritional support should be calculated by maternal serum alimentary values, the weight of the mother and the growth of the fetus. Owing to reduced motility of the gastrointestinal tract in brain-dead patients, special attention should be paid to the management of gastric reflux. Total parenteral nutrition (TPN) during BD in pregnant mothers needs to support a positive nitrogen balance, maternal weight gain, and normal fetal growth and birthweight . The recommended daily allowance for protein during pregnancy is 0.8 g kg-1 day-1 (the normal intake for an average healthy adult) plus an additional 1.3, 6.1 or 10.7 g kg-1 day-1 for the first, second or third trimesters, respectively [29, 30]. In addition, 20-25% of nonprotein calories should be from fat .
There are three sources of infection which should be taken into account during prolonged somatic support: ventilators causing recurrent pneumonia, urinary catheters resulting in bladder and kidney infections and intravascular catheters as a source of septicemia . The majority of reported organisms were typical of nosocomial intensive care unit infections such as Staphylococcus aureus, Actinobacter, Pseudomonas, Hemophilus influenza and fungal pathogens [32, 33]. These infections are usually resistant to antibiotics, and their treatment is challenging. Maternal infections must be treated aggressively with the most effective substances, rather than opting for using substances safe for the fetus, which in turn may not effectively treat the infection [34–36].
The risk of developing deep vein thrombosis is greater during pregnancy because of immobility and flaccid paralysis following BD. Recommended is prophylactic anticoagulation as it is efficacious for the mother and safe for the fetus. For venous thromboembolic disease treatment or prophylaxis during pregnancy, low molecular weight heparin appears to be as safe and effective as unfractionated heparin .
In maternal BD, it is recommended to screen the mother's serum and to examine carefully the fetus by ultrasound to establish that there are no malformations or pathologic findings in the fetal development and no chromosomal abnormalities. In cases with uncertain findings, amniocentesis should be discussed with family members, since the results of these screenings may influence their decisions . In addition, laboratory tests including complete blood cell count, electrolytes such as Na+, Ca2+, K+, creatinine, urea, liver enzymes, retinol-binding proteins, albumin, prealbumin, transferrin and urine analysis should be periodically performed. After 24 weeks of gestation, glucocorticoids should be administered for fetal lung maturation and prophylaxis of fetal respiratory distress syndrome [38, 39]. To prevent preterm uterine contractions, in particular in the early weeks of gestation when no fetal lung maturation is yet provided, tocolytic interventions may be needed. Calcium channel blockers and prostaglandin inhibitors are effective and well tolerated and are therefore preferred to β-mimetic agents [37, 40]. A prolongation of the pregnancy should continue until at least 26 weeks of gestation with a possible second application of glucocorticoids. If maternal and fetal status remain stable, further prolongation of the pregnancy until at least 28 weeks of gestation should be attempted. According to the reported literature, after 32 weeks of gestation and under glucocorticoid-induced fetal lung maturity, no further prolongation of a pregnancy seems necessary. The optimal method of delivery in prolonged maternal somatic support is by cesarean section, as it ensures the least traumatic birth for the fetus. The optimal timing for a cesarean section can be estimated by amniocentesis assessing fetal lung maturity .
Fetal and neonatal considerations
The gestational age and the condition of the fetus, above all lung maturity, are the two most important factors affecting fetal outcome. The majority of studies reported routine and complex fetal monitoring such as daily fetal heart rate monitoring using cardiotocography and nonstress testing. Serial ultrasound examinations to evaluate the fetoplacental unit, including biometric estimations as well as morphologic studies on the placental structure and the amnion fluid, should be performed weekly to assess intrauterine fetal growth [39, 42–44].
Organ donation and transplant outcome
After the delivery of the fetus, a brain-dead mother should be considered as a potential organ donor. Multiorgan instabilities and extensive critical care therapy lasting for weeks may have endangered the organs and caused complications in the recipients. Nevertheless, if one or more organs are still functioning at the time of delivery, the feasibility of organ donation in such catastrophic cases should not be ignored. As reported by Suddaby et al.  in a retrospective review of 252 brain-dead potential donors from 1990 to 1996, five of seven pregnant women functioned as organ donors for 20 transplant recipients. For all of those patients, excellent patient and graft outcomes were reported.
Ethical and legal issues
Many ethical and legal questions arise in cases of maternal BD. Although it was not the focus of this review, we briefly discussed various aspects of ethical and legal issues such as "the mother's body as a cadaveric incubator," "mother as the organ donor and fetus as the recipient" and the concern for "possible damages to the fetus" [31, 45]. Some professionals believe that it is not ethically acceptable to maintain the mother's body after BD to use it as a "fetal container." Such a decision should not be simply assumed, but it must be debated. If the mother is to be considered a "cadaveric incubator" with no autonomous rights, the rights of the fetus should legally prevail. Another argument claims that the prolonged somatic support itself is actually organ donation with the fetus as the recipient. In that case, if the mother had previously indicated a wish to donate her organs, it would be appropriate to proceed with the extended somatic support. Finally, some believe that strategies used to maintain maternal somatic function are still in the experimental stage. Not every adverse effect of medication used on the fetus during an extended somatic support is known. The next of kin must therefore be informed about the existing life maintenance strategies and the possible damages they may cause to the fetus. Psychological consultation should certainly be beneficial in this situation.
Since such catastrophic cases are so infrequent, the mother's wish is in effect rarely known. For this reason, it is strongly suggested to engage the family in the planning of the care. The physician and transplant coordinator should not impose all available procedures against the wishes of the family. Sperling et al.  suggested that questions be answered on a case-by-case basis with the involvement of the hospital's ethics committee. One also needs to consider that while nowadays somatic support in the case of maternal BD is technically possible, there is still no legal document which asks a pregnant woman about the fate of her unborn child in the event of BD. It is highly recommended that this question be added to the advance directives of any woman of childbearing age and routinely discussed in standard prenatal interviews .
At present, BD is a medically and legally accepted event allowing a pronouncement of death. Taking into account that in maternal BD two organisms are involved, the mother and the fetus, a decision whether to maintain the mother's vital functions to allow fetal survival is also an ethical and legal issue. The goal of prolonged maternal somatic support is to deliver a viable and healthy infant with a beneficial long-term outcome. From the medical point of view, the management of a brain-dead pregnant woman should follow the common standards, guidelines and recommendations for organ-preserving therapy. In some situations, however, the mother needs special medical support and interventions which differ from somatic support in nonpregnant BD patients. Both after a successful delivery and in the case of fetal abortion, the mother can also be considered as an organ donor. In general, we recommend that there be no clear lower limit to the gestational age which would restrict the physician's efforts to support the brain-dead mother and her fetus. A meeting of the neurosurgical, critical care, obstetric, neonatal, transplant and ethical staff, along with the patient's family, should collectively make a decision about future treatment steps. Since currently there are still only a limited number of cases describing the management of extended maternal somatic support after brain death, the current recommendations should be continuously reassessed and adapted along with the growing experience and knowledge. For such serious and rare cases as described here, it would be advisable from a clinical point of view to establish an international registry network of BD pregnant patients, which could help to gather further experience. We also think that from the practical point of view, it would be possible to establish such a registry and this network could become a part of routine clinical usage in all neurosurgery and intensive care centers.
Mollaret P, Goulon M: Le coma dépassé. Rev Neurol (Paris). 1959, 101: 3-15.
Suddaby EC, Schaeffer MJ, Brigham LE, Shaver TR: Analysis of organ donors in the peripartum period. J Transpl Coord. 1998, 8: 35-39.
Slattery MM, Morrison JJ: Preterm delivery. Lancet. 2002, 360: 1489-1497. 10.1016/S0140-6736(02)11476-0.
Wood KE, Becker BN, McCartney JG, D'Alessandro AM, Coursin DB: Care of the potential organ donor. N Engl J Med. 2004, 351: 2730-2739. 10.1056/NEJMra013103.
Holmquist M, Chabalewski F, Blount T, Edwards C, McBride V, Pietroski R: A critical pathway: guiding care for organ donors. Crit Care Nurse. 1999, 19: 84-98.
Shemie SD, Ross H, Pagliarello J, Baker AJ, Greig PD, Brand T, Cockfield S, Keshavjee S, Nickerson P, Rao V, Guest C, Young K, Doig C, Pediatric Recommendations Group: Organ donor management in Canada: recommendations of the forum on Medical Management to Optimize Donor Organ Potential. CMAJ. 2006, 174: S13-S32.
Drory Y, Quaknine G, Kosary IZ, Kellermann JJ: Electrocardiographic findings in brain death: description and presumed mechanism. Chest. 1975, 67: 425-432. 10.1378/chest.67.4.425.
Malliani D, Peterson DF, Bishop VS, Brown AM: Spinal sympathetic cardio-cardiac reflexes. Circ Res. 1972, 30: 158-166.
Dictus C, Vienenkoetter B, Esmaeilzadeh M, Unterberg A, Ahmadi R: Critical care management of potential organ donors: our current standard. Clin Transplant. 2009, 23 (Suppl 21): 2-9. 10.1111/j.1399-0012.2009.01102.x.
Hoemme R, Neeser G: Organ donation. Anesthesist. 2007, 56: 1291-1302. 10.1007/s00101-007-1284-8.
Powner DJ: Variables during care of adult donors that can influence outcomes of kidney transplantation. Prog Transplant. 2005, 15: 219-224.
Mallampalli A, Guy E: Cardiac arrest in pregnancy and somatic support after brain death. Crit Care Med. 2005, 33: 325-331. 10.1097/01.CCM.0000182788.31961.88.
Rosengrad BR, Feng RA, Alfrey EJ, Zaroff JG, Emond JC, Henry ML, Garrity ER, Roberts JP, Wynn JJ, Metzger RA, Freeman RB, Port FK, Merion RM, Love RB, Busuttil RW, Delmonico FL: Report of the crystal city meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant. 2002, 2: 701-711. 10.1034/j.1600-6143.2002.20804.x.
Field DR, Gates EA, Creasy RK, Jonsen AR, Laros RK: Maternal brain death during pregnancy. JAMA. 1988, 260: 816-822. 10.1001/jama.260.6.816.
Hevesi ZG, Angelini G, Coursin DB: Supportive care after brain death for the donor candidate. Int Anesthesiol Clin. 2006, 44: 21-34. 10.1097/01.aia.0000210798.53007.4b.
Feldman DM, Borgida AF, Rodis JF, Campbell WA: Irreversible maternal brain injury during pregnancy: a case report and review of the literature. Obstet Gynecol Surv. 2000, 55: 708-714. 10.1097/00006254-200011000-00023.
Bhatia P, Bhatia K: Pregnancy and the lungs. Postgrad Med J. 2000, 76: 683-689. 10.1136/pmj.76.901.683.
Milliez J, Cayol V: Palliative care with pregnant women. Best Pract Res Clin Obstet Gynaecol. 2001, 15: 323-331. 10.1053/beog.2000.0172.
Gramm HJ, Meinhold H, Bickel U, Zimmermann J, von Hammerstein B, Keller F, Dennhardt R, Voigt K: Acute endocrine failure after brain death?. Transplantation. 1992, 54: 851-857. 10.1097/00007890-199211000-00016.
Howlett TA, Keogh AM, Perry L, Touzel R, Rees LH: Anterior and posterior pituitary function in brain-stem-dead donors: a possible role for hormonal replacement therapy. Transplantation. 1989, 47: 828-834. 10.1097/00007890-198905000-00016.
Van Runnard Heimel PJ, Franx A, Schobben AF, Huisjes AJ, Derks JB, Bruinse HW: Corticosteroids, pregnancy, and HELLP syndrome. Obstet Gynecol Surv. 2005, 60: 57-70. 10.1097/01.ogx.0000150346.42901.07.
Smith M: Physiologic changes during brain stem death: lessons for management of the organ donor. J Heart Lung Transplant. 2004, 23 (9 Suppl): S217-S222. 10.1016/j.healun.2004.06.017.
Zhu XA, Li Y: Effect of hyperthermia on the red-cell immune function of rats and its teratogenicity on developing embryos. Wei Sheng Yan Jiu. 2000, 29: 89-91.
Miller MW, Nyborg WL, Dewey WC, Edwards MJ, Abramowicz JS, Brayman AA: Hyperthermic teratogenicity, thermal dose and diagnostic ultrasound during pregnancy: implications of new standards on tissue heating. Int J Hyperthermia. 2002, 18: 361-384. 10.1080/02656730210146890.
Mallampalli A, Powner DJ, Gardner M: Cardiopulmonary resuscitation and somatic support of the pregnant patient. Crit Care Clin. 2004, 20: 747-761. 10.1016/j.ccc.2004.05.005.
Badgett T, Feingold M: Total parenteral nutrition in pregnancy: case review and guidelines for calculating requirements. J Matern Fetal Med. 1997, 6: 215-217. 10.1002/(SICI)1520-6661(199707/08)6:4<215::AID-MFM5>3.0.CO;2-M.
Dominguez-Roldan JM, Murillo-Cabezas F, Santamaria-Mifsut JL, Munoz-Sanchez A, Villen-Nieto J, Barrera-Chacon JM: Changes in resting energy expenditure after development of brain death. Transplant Proc. 1995, 27: 2397-2398.
Rivera-Alsina ME, Saldana LR, Stringer CA: Fetal growth sustained by parenteral nutrition in pregnancy. Obstet Gynecol. 1984, 64: 138-141.
Hamaoui E, Hamaoui M: Nutritional assessment and support during pregnancy. Gastroenterol Clin North Am. 2003, 32: 59-121. 10.1016/S0889-8553(02)00132-2.
Powner DJ, Bernstein IM: Extended somatic support for pregnant women after brain death. Crit Care Med. 2003, 31: 1241-1249. 10.1097/01.CCM.0000059643.45027.96.
Farragher RA, Laffey JG: Maternal brain death and somatic support. Neurocrit Care. 2005, 3: 99-106. 10.1385/NCC:3:2:099.
Catanzarite VA, Willms DC, Holdy KE, Gardner SE, Ludwig DM, Cousins LM: Brain death during pregnancy: tocolytic therapy and aggressive maternal support on behalf of the fetus. Am J Perinatol. 1997, 14: 431-434. 10.1055/s-2007-994175.
Bernstein IM, Watson M, Simmons GM, Catalano PM, Davis G, Collins R: Maternal brain death and prolonged fetal survival. Obstet Gynecol. 1989, 74: 434-437.
Korzeniowski OM: Antibacterial agents in pregnancy. Infect Dis Clin North Am. 1995, 9: 639-651.
Einarson A, Shuhaiber S, Koren G: Effects of antibacterials on the unborn child: what is known and how should this influence prescribing. Paediatr Drugs. 2001, 3: 803-816. 10.2165/00128072-200103110-00003.
Christensen B: Which antibiotics are appropriate for treating bacteriuria in pregnancy?. J Antimicrob Chemother. 2000, 46 (Suppl 1): 29-34. 10.1093/jac/46.suppl_1.29.
Villa-Forte Gomes MP: Venous thromboembolism in pregnancy. Curr Treat Options Cardiovasc Med. 2009, 11: 104-113. 10.1007/s11936-009-0011-y.
Lawson EE: Antenatal corticosteroids: too much of a good thing?. JAMA. 2001, 286: 1628-1630. 10.1001/jama.286.13.1628.
Ferguson S, Allen VM, Craig C, Allen AC, Dodds L: Timing of indicated delivery after antenatal steroids in preterm pregnancies with severe hypertension. Hypertens Pregnancy. 2009, 28: 63-75. 10.1080/10641950802366237.
King JF, Flenady VJ, Papatsonis DN, Dekker GA, Carbonne B: Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst Rev. 2002, CD002255-2
Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM: Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol. 2009, 113: 585-594.
Lewis DD, Vidovich RR: Organ recovery following childbirth by a brain-dead mother: a case report. J Transpl Coord. 1997, 7: 103-105.
Lawson EE: Antenatal corticosteroids: too much of a good thing?. JAMA. 2001, 286: 1628-1630. 10.1001/jama.286.13.1628.
Webb GW, Huddleston JF: Management of the pregnant women who sustains severe brain damage. Clin Perinatol. 1996, 23: 453-464.
Sheikh AA, Cusack DA: Maternal brain death, pregnancy and the foetus: the medico-legal implications for Ireland. Med Law. 2004, 23: 237-250.
Sperling D: Maternal brain death. Am J Law Med. 2004, 30: 453-500.
Catlin A, Volat D: When the fetus is alive but the mother is not: critical care somatic support as an accepted model of care in the twenty first century?. Crit Care Nurs Clin N Am. 2009, 21: 267-276. 10.1016/j.ccell.2009.01.004.
Dillon WP, Lee RV, Tronolone MJ, Buckwald S, Foote RJ: Life support and maternal brain death during pregnancy. JAMA. 1982, 248: 1089-1091. 10.1001/jama.248.9.1089.
Heikkinen JE, Rinne RI, Alahuhta SM, Lumme JA, Koivisto ME, Kirkinen PP, Sotaniemi KA, Nuutinen LS, Järvinen PA: Life support for 10 weeks with successful fetal outcome after fatal maternal brain damage. BMJ. 1985, 290: 1237-1238. 10.1136/bmj.290.6477.1237.
Antonini C, Alleva S, Campailla MT, Pelosi G, Valle E, Verrua M, Zamponi E, Blanda A, Gambaro C: Morte cerebrale e sopravvivebza fetale prolungata [Brain death and prolonged fetal survival]. Minerva Anestesiol. 1992, 58: 1274-1252.
Nettina M, Santos E, Ascioti KJ, Barber MA: Sheila's death created many rings of life. Nursing. 1993, 23: 44-48.
Anstotz C: Should a brain-dead pregnant woman carry her child to full term? The case of the "Erlanger baby.". Bioethics. 1993, 7: 340-350. 10.1111/j.1467-8519.1993.tb00224.x.
Béguin F: Intruduction: La mort cerebrale maternelle [Introduction: maternal cerebral brain death]. Arch Gynecol Obstet. 1993, 253 (Suppl): S1-S3. 10.1007/BF02346790.
Wuermeling HB: Brain-death and pregnancy. Forensic Sci Int. 1994, 69: 243-245. 10.1016/0379-0738(94)90387-5.
Iriye BK, Asrat T, Adashek JA, Carr MH: Intraventricular haemorrhage and maternal brain death associated with antepartum cocaine abuse. Br J Obstet Gynaecol. 1995, 102: 68-69.
Vives A, Carmona F, Zabala E, Fernandez C, Cararach V, Iglesias X: Maternal brain death during pregnancy. Int J Gynaecol Obstet. 1996, 52: 67-69. 10.1016/0020-7292(95)02535-9.
Spike J: Brain death, pregnancy and posthumous motherhood. J Clin Ethics. 1999, 10: 57-65.
Beca JP, Wells W, Rubio R: Muerte cerebral materna durante el embarazo. Rev Med Chile. 1998, 126: 450-455.
Lane A, Westbrook A, Grady D, O'Connor R, Counihan TJ, Marsh B, Laffey JG: Maternal brain death: medical, ethical and legal issues. Intens Care Med. 2004, 30: 1484-1486. 10.1007/s00134-004-2305-6.
Hussein IY, Govenden V, Grant JM, Said MR: Prolongation of pregnancy in a woman who sustained brain death at 26 weeks of gestation. BJOG. 2006, 113: 120-122.
Souza JP, Oliveira-Neto A, Surita FG, Cecatti JG, Amaral E, Pinto e Silva JL: The prolongation of somatic support in a pregnant woman with brain-death: a case report. Reprod Health. 2006, 3: 3-10.1186/1742-4755-3-3.
Mejia R, Badariotti G, De Diego B, Ridruejo O, O'Flaherty E: Brain death in a pregnant woman and fetus survival. Medicina (Buenos Aires). 2008, 68: 447-452.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/8/74/prepub
The authors declare that they have no competing interests.
ME and EK participated in the design of the study and reviewed articles. ME, CD and FSH participated in the design of the study and drafted the manuscript. MG and HF performed the statistical analysis and revised the manuscript. JS, AU, ME, SH and GE were involved in drafting the manuscript or revising it critically for important intellectual content. ME, AM and RA revised the manuscript and gave final approval of the version to be published. All authors read and approved the final manuscript.
Arianeb Mehrabi and Rezvan Ahmadi contributed equally to this work.